Drug Development & Disease Diagnostics
Molecular Basis of Drug Targets & Diseases

Sunnybrook Research Institute
2075 Bayview Avenue, M7 434
Toronto ON M4N 3M5

Summary of Research:

Biotherapies including immunotherapies have had a dramatic impact in terms of patient survival and enhanced quality of life in the areas of inflammatory diseases and cancer. Dr. Gariépy’s laboratory is interested in the design and engineering of protein- and oligonucleotide-based therapeutics aimed at modulating immune responses to either selectively dampen them (anti-inflammatory agents) or release such responses (to target and kill cancer cells). His lab creates and tests such agents by combining synthetic, combinatorial and genetic approaches with cellular assays and animal studies. The team also designs probes and devises new methods that can serve as new diagnostic or discovery tools. Additionally, they collaborate with clinicians and scientists at Sunnybrook Research Institute and elsewhere in the world as what they do is applicable to any disease.

A further description of our research endeavours can be found at

Recent Publications

Ma YV, Sparkes A, Romão E, Saha S, Gariépy, J., (2021). Agonistic nanobodies and antibodies to human VISTA. MAbs. 2021 Jan-Dec;13(1):2003281. doi: 10.1080/19420862.2021.2003281.  

Alwash M, Gariépy, J., (2022). Labeling cell surface receptors with Ligand.BirA* bispecifics.  ACS Pharmacol. Transl. Sci. 2022, 5, 2, 62–69

Additional Publications